Acta Biomedica Scientia

e - ISSN - 2348 - 2168
Print ISSN - 2348 - 215X

www.mcmed.us/journal/abs

Research Article

PHARMACOLOGY OF ANTI-INFLAMMATORY DRUGS: MECHANISMS, CLINICAL APPLICATIONS, SAFETY CONCERNS, AND EMERGING TARGETED THERAPIES

Lavanya A*, Rakesh B, Keerthi B, Sankeerthana P, Sneha Rani G

KLR Pharmacy College, Paloncha, Telangana, India.

ABSTRACT

Anti-inflammatory medications are critical therapeutic solutions that are used in the management of inflammation, pain, swelling and fever in a broad spectrum of acute and chronic illnesses. Inflammation is a protective mechanism of immune cells and chemical messengers, which include, but are not limited to, prostaglandins, leukotrienes, cytokines, and histamine; nevertheless, long-term inflammation is a contributory factor to diseases, such as rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, and other autoimmune diseases. The pharmacology of the key anti-inflammatory drug classes such as non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, disease-modifying anti-rheumatic drugs (DMARDs), biologics, and novel small molecules are described. Blocking the synthesis of prostaglandins through the use of cyclooxygenase enzymes, corticosteroids through the use of phospholipase A 2 and inflammatory gene expression, NSAIDs and corticosteroids, respectively, have a potent immunomodulatory effect. Especially the long term safety issues, especially gastrointestinal, renal, metabolic, and infection-related risks are highlighted. New specific treatment methods like biologic therapy and JAK-inhibitors provide selective anti-inflammatory control and better disease management.

Keywords: - Anti-inflammatory drugs, Cyclooxygenase pathway, Corticosteroids, Biologic therapies, Chronic inflammation.

INTRODUCTION

Inflammation is one of the basic biological reactions which allows the organism to defend itself against trauma, infection, and other unpleasant factors. It is a complicated web of cellular and molecular processes that are mediated by immune cells, vascular responses and chemical mediators like prostaglandins, leukotrienes, cytokines and histamine [1–5]. Although acute inflammation is necessary to repair tissues and protect the body, unregulated or prolonged inflammation is one of the causes of many chronic diseases, such as rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, asthma and autoimmune diseases. The necessity to regulate the excessive inflammatory reactions and, at the same time, not to activate protective immunity to its full extent has resulted in the emergence of an extensive repertoire of anti-inflammatory medications. These drugs comprise a significant group of medicines in contemporary medicine that alleviates pain, swelling, fever, and tissue trauma that comes with inflammatory diseases. Pharmacology of anti-inflammatory drugs includes the mechanism of action on the inflammatory pathway, pharmacokinetics of the drugs in the body, the use of anti-inflammatory drugs, and the possible side effects [6,7]. Generally, the anti-inflammatory medications can be classified into non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, disease-modifying anti-rheumatic drugs (DMARDs), new targeted therapy, including biologics and small-molecule inhibitors.

NSAIDs have an action of primarily inhibiting cyclooxygenase enzymes, aiding in the production of prostaglandin and consequently delivering analgesic, antipyretic, and anti-inflammatory effects. Corticosteroids have stronger effects in inhibiting the activity of phospholipase A 2 and decrease the expression of inflammatory genes, resulting in the production of fewer cytokines and the activation of immune cells. DMARDs and bioagents go even further to address therapeutic interventions by focusing on particular immune actions that cause chronic inflammation and autoimmune pathology. The clinical utility of the anti-inflammatory drugs can be seen through the extensive use of drugs in acute disorders like trauma and

Corresponding Author: **Lavanya A** Email: arebonialavanya31@gmail.com

inflammatory diseases in post operation and in chronic diseases that demand long term restraint of immune mediated injury. Their advantages, however, frequently are constrained by their side effects in terms of gastrointestinal, renal, cardiovascular, metabolic and immunological systems, especially when used over a long period of time. NSAIDs are linked to gastrointestinal ulceration and renal failure whereas corticosteroids are linked to osteoporosis, hyperglycemia, adrenal inhibition and predisposition to infections [7–9]. The above limitations have prompted the discovery of more effective and safer forms of therapy that can control inflammation at its molecular basis. Immunology and biotechnology have resulted in the creation of biologics that are selective neutralizers of inflammatory cytokines and novel small-molecule drugs that are selective inhibitors of intracellular signaling pathways like JAK150 STAT and NF- 0. These later agents are a change of generalized suppression of inflammation to a specific control of immune reactions being more effective with less systemic toxicity. Knowledge of the pharmacology of anti-inflammatory medicines is thus necessary in rational selection of drugs, proper administration, and safe long-time administration of patients with inflammatory diseases. A comprehensive understanding of inflammatory processes, pharmacological effects, clinical indicators, and adverse reactions offers the basis of successful therapeutic treatment and indicates the current role of specific anti-inflammatory treatment in enhancing patient outcomes.

ANTI - Inflammatory drugs Pharmacology

A significant group of therapeutic agents that is beneficial in reducing inflammation, pain, swelling, and fever are called anti-inflammatory drugs and are used in a broad variety of diseases that may include arthritis, trauma, infections and autoimmune diseases. Inflammation refers to a biological response to harmful stimuli (pathogens, damaged cells, or irritants), which is a protective reaction, and it is characterized by a complex interaction of immune cells, blood vessels, and chemical mediators. Pharmacology of anti-inflammatory drugs is concerned with the effect of these agents on the pathways of inflammation, absorption and distribution of that agent in the body, metabolism and elimination of the agent and therapeutic and adverse effects of these agents. The drugs primarily act through the inhibition of the production/activity of inflammatory mediators, including prostaglandins, leukotrienes, cytokines, histamine, and bradykinin. Anti-inflammatory drugs can be broadly described as non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and disease-modifying anti-rheumatic drugs (DMARDs) based upon the mechanism of action [10, 11]. Inhibitors of the effects of cyclooxygenase (COX) enzymes involved in the production of prostaglandins are the major NSAIDS and thus prevent pain and inflammation. The action of corticosteroids is to inhibit the activity of phospholipase A 2 and reduce the synthesis of various inflammatory mediators, which leads to a greater anti-inflammatory effect. Newer biological agents and DMARDs also focus on certain immune pathways that are responsible in such long-term inflammatory conditions like rheumatoid arthritis. Pharmacokinetically, majority of the anti-inflammatory agents are well-absorbed enterally, highly protein bound and have hepatic metabolism, excreted either renal or bile. Their clinical application should be well balanced with their side effect profile that involves gastrointestinal irritation, kidney impairment, cardiovascular risks, immunosuppression and hormonal disruption depending on the type of the drug. Clearly, to be able to choose the right agent, dose and duration of the treatment to reach the best therapeutic effect and reduce the number of adverse events, it is necessary to comprehend the pharmacology of the anti-inflammatory drugs [12,13]

General. This report will provide a comprehensive overview of the field of anti-inflammatory medications and the pharmaceutical companies that produce them.

Anti-inflammatory drugs are the drugs that are aimed at regulating or suppressing the inflammatory reaction of the body which is one of the primary defensive mechanisms of the body against injury, infection and tissue damage. Classical features of inflammation include redness, heat, swelling, pain and loss of function, and it is mediated by the release of different chemical substances of damaged tissues and immune cells[14,15]. Although inflammation is very helpful during the first few days of healing, excessive or sustained inflammation may cause the destruction of tissue and chronic illness. Anti-inflammatory medicines are very crucial in the treatment of acute and chronic inflammatory diseases by lowering these adverse effects. The drugs are usually used in treating rheumatoid arthritis, osteoarthritis, asthma attacks, allergic reactions, inflammatory bowel disease, and after surgery. The ultimate aim of an anti-inflammatory treatment is to alleviate the symptoms like pain and swelling besides ensuring that no additional tissue loss occurs. Anti-inflammatory agents can have different activities in the cascade of inflammation by inhibiting the production or action of inflammatory mediators. As an illustration, NSAIDs prevent the formation of prostaglandins, corticosteroids inhibit the activation of immune cells and the release of cytokines, and the biological agents block the action of certain inflammatory cytokines such as tumor necrosis factor (TNF) and interleukins[16–18]. Anti-inflammatory drugs can be used to offer

symptomatic relief, or alter the disease history of chronic inflammatory diseases depending on their mechanism. The drugs can be administered in different dosages such as tablets, injections, topical preparations and inhalers which means that they can be used flexibly in clinical settings. Nonetheless, all of their therapeutic advantages are usually accompanied by the possible side effects, e.g. gastric irritation, immune impairment, metabolic imbalances, and hormonal disorders. Thus, the rational use of anti-inflammatory medications implies a clear comprehension of the disease process, mechanism of working of the drug, and specifics of a patient. Inflammatory drugs are still invaluable in the contemporary pharmacotherapy because of their broad scope of application and the ability to manage the inflammatory disorders.

Mechanism of Inflammation and Action of drugs

Inflammation is a multifaceted biological reaction that is launched by the body to shield the tissues against damage, attack, or other dangerous substances. It consists of a complex of events mediated by immune cells, changes in vases, and chemical mediators called inflammatory mediators[19,20]. It starts with the tissue damage or invasion of pathogen which results in the release of such mediators as histamine, prostaglandin, leukotrienes, cytokines, and chemokine released by mast cells, macrophages, and injured cells. These mediators augment vascular permeability and bring about vasodilation leading to redness and swelling, and also activate the sensory nerve endings to generate pain. Migration of leukocytes to the injury site is known as chemotaxis in which the leukocytes attach themselves to the pathogen and secrete enzymes and reactive oxygen species to destroy harmful entities. Though this reaction is protective in nature, it might cause disease and tissue destruction in case of excessive or prolonged inflammation. The action of anti-inflammatory drugs is to disrupt one or more stages in this inflammatory cascade[21,22]. There are those drugs that suppress the production of mediators, others prevent the receptors of the mediators, and there are those that prevent the activation and growth of immune cells. Indicatively, NSAIDs decrease the synthesis of prostaglandins, corticosteroids decrease the expression of inflammatory genes, and the biological agents counteract the effect of certain cytokines. Pharmacological regulation of inflammation is meant to lessen the pain, swelling as well as tissue damage without fully suppressing the immune response. The key to the choice of the therapeutic regimen and the possibility of predicting therapeutic results and adverse reactions is the understanding of the mechanisms of inflammation and the action of drugs. Anti-inflammatory medications are used to treat the patient with inflammatory diseases by attacking the major inflammatory signaling and enzymes to reestablish the functionality of normal tissues and the quality of life of the patient [23,24].

NSAIDs and Cyclooxygenase Pathways

Cyclooxygenase (COX) pathway is the key element of the inflammatory process as it facilitates the transformation of arachidonic acid to thromboxanes and prostaglandins, which are very crucial in mediating pain, fever and inflammation[25,26]. The release of arachidonic acid is mediated by the phospholipase A 2 enzyme when cell membrane phospholipids are damaged or when the immune system becomes activated. This is then broken down to two principal isoforms of the cyclooxygenase enzyme; COX-1 and COX-2. COX-1 is expressed in most tissues constitutively and produces prostaglandins that are involved in functions of the body like protection of the stomach mucosa, maintenance of renal blood flow and platelet aggregation. By comparison, COX-2 is a stimulable enzyme that is stimulated at inflammatory sites in response to cytokines and growth factors, thus enhancing the synthesis of the pro-inflammatory prostaglandins. Non-steroidal anti-inflammatory drugs (NSAIDs) have their therapeutic effects by mainly acting on the COX enzymes, which makes them decrease the production of the prostaglandin. The anti-inflammatory, analgesic and antipyretic effects of the non-selective NSAIDs, like aspirin, ibuprofen, and diclofenac, are due to their selective inhibition of both COX-1 and COX-2. Nonetheless, COX-1 inhibition also causes such negative events as gastric irritation, ulceration, and bleeding. Selective COX-2 inhibitors such as celecoxib have been developed with the aim of reducing the amount of gastrointestinal toxicity and maintaining the anti-inflammatory effects. NSAIDs decrease vasodilation, edema, and pain sensitization of inflammatory sites by decreasing the levels of prostaglands. Therefore, the cyclooxygenase pathway modulation is one of the pharmacological approaches in the treatment of inflammatory and pain disorders[27,28].

Immunomodulators and Corticosteroids.

Corticosteroids are very strong anti-inflammatory and immunosuppressive drugs which affect their action by regulating the expression of genes and repressing various factors of inflammatory reaction. These medications are artificial parallels of the natural glucocorticoids which are secreted by the adrenal cortex, and they occur by diffusing through cells and binding to the intracellular glucocorticoid receptors[29,30]. This drug-receptor complex is then translocated to the nucleus where it binds to certain DNA sequences to either increase or decrease the transcription of different genes that are involved in inflammation and immune activity.

Corticosteroids prevent the expression of pro-inflammatory cytokines (interleukins, tumor necrosis factor- 2, and interferon-G) and induce the production of anti-inflammatory ones (lipocortin). With the help of lipocortin, phospholipase A 2 is inhibited and the release of arachidonic acid and consequently enhancement of prostaglandins and leukotrienes are lessened. Moreover, the corticosteroids suppress capillary permeability, prevent the migration of leukocytes to inflammatory areas, and decrease the macrophage and lymphocyte functionality. The outcomes of such actions include a significant reduction in redness, swelling, pain, and tissue damages. Due to their extensive and potent actions, corticosteroids have many applications in the management of autoimmune diseases, allergic disorders, asthma and inflammatory disorders of different organs[31,32]. Their immunosuppressive effect however causes more susceptibility to infection and with prolonged use there is adverse effect of osteoporosis, hyperglycemia, adrenal suppression, and Cushingoid appearance. Thus, the administration of corticosteroids should be reasonable, dose, and time should be monitored to attain good immune control with minimal risks.

It can be used clinically as anti-inflammatory drugs

The anti-inflammatory medications are widely utilized in medical practice to treat a broad range of ailments in which the inflammation is a primary pathological process[33,34]. Their main goal is to decrease the pain, swelling, stiffness and functional impairment in the course of inflammatory processes, which enhance the comfort and quality of life of a patient. The drugs are used in acute disorders like trauma, postoperative inflammation, infections and chronic disorders like arthritis, asthma, and autoimmune diseases. The selection of the anti-inflammatory agent will rely on the nature and severity of the disease, pathophysiology in the patient, age, comorbidities and risks of adverse effects[35,36]. The non-steroidal anti-inflammatory drugs are usually applied in mild to moderate inflammatory diseases and give symptomatic treatment by relieving pain and swelling. The use of corticosteroids is reserved to cases of increased severity or refractions as it has been found to have strong anti-inflammatory and immunosuppressive effects. The disease-modifying anti-rheumatic and biological medications are doing so by modifying the disease trajectory of chronic inflammatory and autoimmune diseases by addressing certain immune pathways. The choice of route of administration of the anti-inflammatory drugs can be oral, parenteral, topical, or inhalational depending on the location and nature of the inflammation. Combination therapy has been used in most situations to allow the treatment of symptoms with maximum control and minimum toxicity. As an example, in rheumatoid arthritis NSAIDs can be used together with DMARDs or corticosteroids could be used temporarily during the exacerbation of the disease. Although they have positive effects, there is a lot of adverse effects linked with the long-term use of anti-inflammatory drugs, including gastrointestinal damage, renal dysfunctions, cardiovascular risks, and immunosuppression. As such, clinical use involves close evaluation of benefit-risk ratio, dose response, and close focus. All in all, anti-inflammatory medications will continue to be invaluable resources in the contemporary healthcare industry providing a viable way to manage a variety of inflammatory diseases and play a significant role in patient care.

Rheumatoid Arthritis and Osteoarthritis

Two typical examples of chronic joint diseases in which inflammation significantly contributes to the pathogenesis are rheumatoid arthritis and osteoarthritis, the etiology of which is considerably different. Rheumatoid arthritis is an autoimmune disorder that is marked by it being persistent in the inflammation of the synovia, swelling of joints, pain, and the progressive destruction of cartilage and bone[37,38]. The use of anti-inflammatory medications forms a foundation of treatment in rheumatoid arthritis, and the purpose of these medications is to relieve painful experiences, decrease inflammation, and eliminate permanent damage to joints. NSAIDs have been widely practiced to provide symptomatic pain and stiffness relief whereas corticosteroids have been utilized to suppress inflammation quickly during acute flare-ups. But the long term management of the disease is done by administration of disease-modifying anti-rheumatic drugs like methotrexate and cytokine-targeting biological agents like tumor necrosis factor and interleukin-6. These substances do not only lessen the inflammation but also delay the course of the disease and maintain the functionality of joints. Conversely, osteoarthritis is more of a degenerative arthritis disease, which is related to a breakdown in cartilage albeit the presence of inflammatory mediators in contributing to pain and swollen joints[39,40]. Anti-inflammatory drugs are primarily employed because they reduce symptoms instead of altering the course of the disease in osteoarthritis. NSAIDs are a common type of medication that is given to limit pain and enhance mobility. Short-term relief can be done through intra-articular corticosteroid injections in severe cases. The therapy of both disorders is centered on the need to balance between good pain management and good reduction of adverse effects especially in older patients who are more prone to drug toxicity. Therefore, anti-inflammatory medications are important in the treatment of rheumatoid

arthritis as it addresses immune-mediated inflammation, and in osteoarthritis as it helps in alleviating inflammatory pain and enhances functional ability [41,42].

Autoimmune Disorders and Inflammatory Bowel Disease.

Inflammatory bowel disease and autoimmune disorders are the examples of disorders where deregulated immune responses cause chronic inflammation and tissue destruction. The inflammatory bowel disease, which involves Crohn and ulcerative colitis, is an enduring inflammatory process of the gastrointestinal tract, which causes abdominal pain, diarrhea, bleeding, and weight loss. Anti-inflammatory medications are the basis of treatment in the inflammatory bowel disease, and the main objective is the relapse and remission[43–45]. Mesalamine is an aminosalicylate which is used in mild to moderate disease and works locally on the intestinal mucosa to inhibit the release of inflammatory mediators. A moderate to severe exacerbation is treated by corticosteroids to suppress the inflammatory process and the immune response. In patients with refractory disease, azathioprine and methotrexate are used as immunomodulators, and tumor necrosis factor, integrin biological agents are used to reduce immune-mediated inflammation and complications prevention. Autoimmune diseases like systemic lupus erythematosus, multiple sclerosis and psoriasis also relate to chronic stimulation of immune systems over self-antigens. Under such circumstances, anti-inflammatory drugs can be used to lower tissue inflammation and organ injury by inhibiting the activity of immune cells, as well as the production of cytokines. Corticosteroids are still central to acute disease exacerbations, whereas disease-modifying agents and biological treatments offer long-term disease control by specific immune mechanism. To be able to use anti-inflammatory drugs in treating these disorders, patients need to be given individual therapy, depending on the severity of the disease, and the organ and patient tolerance. All in all, anti-inflammatory medications play a key role in the treatment of inflammatory bowel disease and autoimmune diseases to regulate immune-mediated inflammation, alleviate the symptoms and enhance long-term outcomes[46,47].

Side Effects and Long-term Use Control.

Despite the fact that anti-inflammatory drugs are very effective in managing pain and inflammation, their developmental application is usually constrained by the eventual development of adverse effects particularly within the case of long-term administration or high doses[48]. These drugs are associated with the risk of toxicity because most of the inflammatory mediators that these drugs are directed to are also important physiologically in the normal functioning of organs. Persistent inhibition of these mediators thus can interfere with protective mechanisms of different tissues. Non-steroidal anti-inflammatory drugs are linked to gastrointestinal, renal, and cardiovascular complications, whereas corticosteroids cause disturbances in the metabolism, endocrine, musculoskeletal, and immunological[49–51]. Age, dose, length of treatment, and comorbidity to peptic ulcer disease, hypertension, diabetes, or renal impairment are some of the factors that determine the likelihood of adverse effects. On-going anti-inflammatory medication can also conceal the progressive development of the disease and results in late diagnosis and treatment of the complication. Additionally, interactions between drugs may raise the toxicity like the use of NSAIDs with anticoagulant or corticosteroids which greatly increases chances of gastro intestinal bleeding. Besides that, chronic immunosuppression due to corticosteroids and some biological agents predisposes the body to infections and can hinder its ability to heal wounds. Thus, the selection of patients, the use of proper dosing schedules and constant control of clinical and laboratory parameters are critical in the case of the prolonged use of the anti-inflammatory drugs. Therapy should always aim at administration of minimal yet effective dose within the shortest time possible with the required degree of symptom and disease activity control[52–54]. This knowledge of the possible negative outcomes and long-term issues is essential to the maximization of therapeutic results and the safety of patients.

Gastrointestinal and renal toxicity

Some of the most severe side effects of using non-steroidal anti-inflammatory drugs in the long run include gastrointestinal and renal toxicity. The main effects of the application in gastrointestinal toxicity are due to inhibition of the cyclooxygenase-1 enzyme that produces prostaglandins that protect gastric mucosa by secreting mucus and bicarbonates and ensuring sufficient blood flow. A decrease in these protective prostaglandins exposes the gastric lining to acid injury, causing gastritis, peptic ulcer and gastrointestinal bleeding[55,56]. The symptoms can vary between mild dyspepsia and heartburn to serious and fatal complications like perforation and hemorrhage. Elderly patients, patients with history of ulcers, patients taking combination of NSAID, anticoagulants and corticosteroids are at higher risk of gastrointestinal toxicity. The toxicity of renal occurs due to the fact that the prostaglandins have a significant role in sustaining renal blood flow particularly in the instance of low circulating volume or renal perfusion. Prostaglandin synthesis inhibition may

cause a drop in glomerular filtration rate, sodium and water retention and hypertension. Longevity use of NSAIDs can lead to acute renal failure, interstitial nephritis or exacerbation of the underlying renal failure. These effects are especially dangerous to patients who have dehydration, heart failure, or chronic kidney disease. In order to reduce gastrointestinal and renal toxicity, the general approach includes the lowest effective dose, administration of gastroprotective measures like proton pump inhibitor and the avoidance of NSAIDs in the high-risk patients. Therefore, NSAIDs should be closely monitored and prevented especially in long-term usage.

Side Effects of Corticosteroids.

Corticosteroids are effective anti-inflammatory and immunosuppressive, and long-term use is linked to various adverse effects because of their impact on various metabolic and hormonal pathways[57,58]. Among the most noticeable effects is suppression of the hypothalamic-pituitary-adrenal axis which may result into adrenal insufficiency in case treatment is suddenly withdrawn. There are also metabolic changes associated with prolonged corticosteroid use which includes hyperglycemia, insulin resistance and body fat redistribution leading to typical appearances such as moon face, truncal obesity and buffalo hump. Musculoskeletal, osteoporosis, muscle wasting, and the risk of fracture are the musculoskeletal effects that are caused by the impaired calcium metabolism and bone formation. Corticosteroids also compromise the immune system by impairing the functioning of leukocytes and the production of cytokines thus predisposing one to infections and slowing down wound healing. There is the risk of gastrointestinal complications like peptic ulceration and gastrointestinal bleeding especially in the combination of corticosteroids with NSAIDs. There have also been neuropsychiatric effects such as mood change, insomnia, depression and psychosis. Long-term administration of corticosteroids may retard growth and development in children. Also, with the long-term use, one can develop cataraks, glaucoma and skin alterations, including skin thinning, bruises, and delayed healing. Due to these side effects, the lowest possible dose of corticosteroid should be taken in the shortest time. Tapering of the doses should be done gradually to avoid adrenal suppression and Stevens should take frequent blood glucose, bone density, blood pressure level and infection signs to ensure successful and safe treatment.

New Ways in Anti-inflammatory Therapy

More recent developments in the field of both immunology and molecular biology have given rise to newer methods in the form of anti-inflammatory therapy which are expected to offer more effective and safer methods of treatment in case of chronic inflammatory diseases. Conventional anti-inflammatory agents like the NSAIDs and corticosteroids have a general effect in inflammatory processes and may be linked with considerable adverse effects in the course of prolonged consumption. In comparison, more recent methods of treatment are aimed at the selective attack on the main molecules and signaling pathways of the inflammatory process. This is a precision-based method, which aims at suppressing pathological inflammation without damaging normal immune function. Biotechnological advances have made possible the development of monoclonal antibodies, receptor antagonists and fusion proteins, which precisely inhibit the effects of inflammatory mediators like tumor necrosis factor, interleukins and adhesion molecules[59–61]. Moreover, innovation in drug discovery has discovered new intracellular targets such as kinases and transcription factors which control the activation of immune cells and cytokine production. The developments have revolutionized the management of diseases like rheumatoid arthritis, psoriasis, inflammatory bowel disease and ankylosing spondylitis by providing better control of the symptoms and modification of the disease. Besides, the genomic medicine is gaining relevance in the area of anti-inflammatory therapy because genetic and biomarker-based profiling allows predicting the response of patients to certain therapies. Taking of targeted therapies in combination with conventional drugs can be used to achieve combination regimens that increase efficacy and decrease toxicity. Although they have a promise, the new approaches are linked to the following problems: high cost, risk of infections and development of drug resistance or loss of response with time. Therefore, constant research and clinical trials are crucial to maximize their utilization and increase their use to other inflammatory diseases. Altogether, the new directions in the anti-inflammatory treatment can be viewed as the shift in the nonspecific suppression of inflammatory state to the specific regulation of immune systems as the hope of safer and more effective long-term treatment of inflammatory disorders.

Biologics and Specific Direction of Inflammation

The biologics are manmade therapeutic agents that are genetically engineered using living cells which are tailored to further attack the necessary components of the immune system which take part in the inflammation process. They are monoclonal antibodies, receptor antagonists and fusion proteins that neutralize pro-inflammatory cytokines or their receptors. The initial biologics used in the treatment of chronic inflammatory conditions include tumor necrosis factor inhibitors including infliximab, adalimumab, and etanercept and have proven to be remarkably effective in the treatment

of diseases like rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Other biologics include interleukin-1, interleukin-6, interleukin-17 and interleukin-23 which are important in the activation and the maintenance of the chronic inflammation in the immune cells. Inhibiting these cytokines selectively in biologics lowers the inflammation source and is able to inhibit structural degradation of tissues and organs. Inflammation-specific modulation also involves agents which disrupt the movement of immune cells, e.g. integrin-inhibitors, which inhibit the movement of leukocytes to inflamed tissues. Biologics has high specificity, which leads to better treatment and reduced off-target effects than the usual anti-inflammatory drugs. Their immunosuppressive effect may, however, predispose to infections, and opportunistic infections like tuberculosis, and may predispose patients to malignancies in the long term. Biologic agents are typically injected or infused, and need to be selected and monitored with care in patients. In spite of these shortfalls, biologics have transformed the management of chronic inflammatory and autoimmune diseases with disease-modifying capabilities and prolonged control of inflammatory processes through specific immune control.

Small Molecules Novelty: Chronic Inflammation.

There is also new small-molecule drugs as alternative agents in chronic inflammatory conditions in addition to biologics. These are normally chemically produced and programmed to act on particular intracellular signaling pathways which control the activation of immune cells and cytokine generation. Janus kinase inhibitors are one such group of small-molecule anti-inflammatory agents, which inhibit the JAK–STAT signaling pathway by which signals of the cytokine are transmitted to the nucleus by cell surface receptors. JAK inhibitors suppress this pathway and decrease the generation of various inflammatory compounds and have been effective in rheumatoid arthritis and ulcerative colitis. Other novel small molecules include phosphodiesterase-4, mitogen-activated protein kinases and nuclear factor kappa B that are major regulators of immune response and inflammation. Small-molecule drugs are administered orally when compared to biologic, which is more convenient and has a better patient response. They also possess less half-lives, hence they can be administered more flexibly and the side effects easily controlled. Nonetheless, since they tend to induce intracellular pathways which are common to several cell types, they may still induce off-target effects like gastrointestinal upset, liver toxicity or hematological abnormalities. The emergence of these agents indicates a change in direction to precision pharmacology, wherein disease-modifying agents have been developed to disrupt specific molecular targets of chronic inflammation. With further research, additional small molecules will increase the number of therapeutic options, complement biologic therapies and offer more affordable and readily available therapy to chronic inflammatory disease patients.

Table 1: Key Classes of Anti-inflammatory Drugs: Examples, Mechanisms, and Main Uses

Drug class	Common examples	Primary mechanism of action	Major clinical uses	Key limitations/concerns
NSAIDs (non-selective)	Aspirin, Ibuprofen, Diclofenac, Naproxen	Inhibit COX-1 & COX-2 → ↓ prostaglandins	Pain, fever, acute inflammation, OA, RA (symptom relief)	GI irritation/ulcer, renal toxicity, bleeding risk
COX-2 selective NSAIDs	Celecoxib	Preferential COX-2 inhibition → ↓ inflammatory prostaglandins	OA, RA, inflammatory pain (less GI toxicity)	CV risk (thrombosis), renal effects still possible
Corticosteroids	Prednisolone, Dexamethasone, Hydrocortisone	↓ PLA_2 activity + ↓ inflammatory gene expression	Severe inflammation, asthma, autoimmune flares, IBD flare	Immunosuppression, metabolic & bone effects
Conventional DMARDs	Methotrexate, Sulfasalazine	Suppress immune activation (disease-modifying)	RA and other autoimmune disorders	Slow onset, liver/bone marrow toxicity
Biologics	Infliximab,	Block TNF/ILs or immune cell trafficking	RA, IBD, psoriasis,	Infection risk (TB), cost, injection/infusion
Novel small molecules	Tofacitinib	Inhibit	RA, IBD, chronic inflammation	Infection risk, lab monitoring, drug interactions

Table 2: Inflammation Pathway Targets and How Drugs Interrupt the Cascade

Step in inflammation	Key mediator/process	Major effect in the body	Drug target/strategy	Drug group acting here
Membrane mediator release	Phospholipase A_2 releases	Initiates prostaglandin/leukotriene synthesis	Inhibit PLA_2 & gene expression	Corticosteroids
Prostaglandin production	COX-1/COX-2 pathway	Pain sensitization, fever, vasodilation,	COX inhibition	NSAIDs, COX-2 inhibitors
Leukotriene production	Lipoxygenase	Bronchoconstriction,	Leukotriene pathway inhibition	(Relevant in asthma; add-on therapy)
Cytokine amplification	TNF-α, IL-1, IL-6, IL-17	Sustains chronic inflammation & tissue damage	Neutralize cytokines/receptors	Biologics
Immune cell recruitment	Integrins	Leukocyte migration to inflamed tissue	Block trafficking	Integrin inhibitors (biologics)
Intracellular	JAK–STAT, NF-	Drives cytokine gene expression	Inhibit	JAK inhibitors, other small molecules

Table 3: Adverse Effects of NSAIDs and Corticosteroids: Organ-wise Summary + Prevention

Drug group	System affected	Common adverse effects	High-risk patients	Prevention/monitoring tips
NSAIDs	Gastrointestinal	Gastritis, ulcer, GI bleeding	Elderly, ulcer history, anticoagulant users	Use lowest dose, add PPI, avoid alcohol, monitor symptoms
NSAIDs	Renal	↓ GFR, fluid retention, AKI	CKD, dehydration, heart failure	Avoid long-term use, monitor
NSAIDs	Cardiovascular	Hypertension, thrombotic risk (↑ with COX-2)	CAD, stroke risk patients	Prefer safer options, monitor BP, use caution with COX-2
Corticosteroids	Endocrine/metabolic	Hyperglycemia	Diabetes, obesity	Monitor glucose, lifestyle advice, taper dose gradually
Corticosteroids	Bone/muscle	Osteoporosis, fractures, muscle wasting	Postmenopausal women, elderly	Calcium/
Corticosteroids	Immune system	Increased infections, poor wound healing	TB risk,	Screen TB when needed, monitor infections, vaccinate appropriately
Corticosteroids	Eyes/skin/CNS	Cataract, glaucoma, skin thinning, mood changes	Long-term users	Eye check-ups, counsel on mood/sleep, use lowest dose

Figure 1: Mechanisms of Inflammation and Sites of Action of Anti-inflammatory Drugs	Figure 2: Clinical Applications of Anti-inflammatory Drugs in Acute and Chronic Diseases	Figure 3: New Approaches in Anti-inflammatory Therapy: Biologics and Novel Small Molecules
		

CONCLUSION

The pharmacology of anti-inflammatory drugs has evolved from broad-spectrum agents to more targeted therapies. Traditional treatments like NSAIDs and corticosteroids are effective but come with significant adverse effects. The advent of disease-modifying anti-rheumatic drugs and biologics has improved management of chronic inflammatory and autoimmune diseases by targeting specific immune pathways. Small-molecule inhibitors targeting intracellular signaling pathways, such as JAK-STAT and NF-kB, offer more precise, oral treatments. However, challenges remain, including high treatment costs, infection risks, safety concerns, and patient variability, highlighting the need for personalized medicine. Ongoing research into new targets and therapies will enhance the efficacy and safety of anti-inflammatory treatments, ultimately improving patient outcomes.

REFERENCES

1. Choi, Y., Lee, S., Kim, H. J., Park, T., Kwack, W. G., Yang, S., et al. (2025). State-of-the-art evidence for clinical outcomes and therapeutic implications of Janus kinase inhibitors in moderate-to-severe ulcerative colitis: A narrative review. *Pharmaceuticals*, 18, 740.
2. Herrera-Deguise, C., Serra-Ruiz, X., Lastiri, E., & Borruel, N. (2023). JAK inhibitors: A new dawn for oral therapies in inflammatory bowel diseases. *Frontiers in Medicine*, 10.
3. Słuczanowska-Głąbowska, S., Ziegler-Krawczyk, A., Szumilas, K., & Pawlik, A. (2021). Role of Janus kinase inhibitors in therapy of psoriasis. *Journal of Clinical Medicine*, 10, 4307.
4. Wood, H., Chandler, A., Nezamololama, N., Papp, K., & Gooderham, M. J. (2021). Safety of Janus kinase (JAK) inhibitors in the short-term treatment of atopic dermatitis. *International Journal of Dermatology*, 61, 746–754.
5. Sabaawy, H. E., Ryan, B. M., Khiabanian, H., & Pine, S. R. (2021). JAK/STAT of all trades: Linking inflammation with cancer development, tumor progression, and therapy resistance. *Carcinogenesis*, 42, 1411–1419.
6. Koushki, K., Biswal, P., Vijay, G. V., Sadeghi, M., Dehnavi, S., Tra, N. T., et al. (2025). Immunomodulatory effects of gold nanoparticles: Impacts on immune cells and mechanisms of action. *Nanomaterials*, 15, 1201.
7. Narayanan, K. B. (2025). Enzyme-based anti-inflammatory therapeutics for inflammatory diseases. *Pharmaceutics*, 17, 606.
8. Ren, J., Fok, M. R., Zhang, Y., Han, B., & Lin, Y. (2023). The role of non-steroidal anti-inflammatory drugs as adjuncts to periodontal treatment and in periodontal regeneration. *Journal of Translational Medicine*, 21.

9. Domper Arnal, M.-J., Hijos-Mallada, G., & Lanas, A. (2021). Gastrointestinal and cardiovascular adverse events associated with NSAIDs. *Expert Opinion on Drug Safety*, 21, 373–384.
10. Khalil, N. A., Ahmed, E. M., Tharwat, T., & Mahmoud, Z. (2024). NSAIDs between past and present; a long journey towards an ideal COX-2 inhibitor lead. *RSC Advances*, 14, 30647–30661.
11. Drożdżal, S., Lechowicz, K., Szostak, B., Rosik, J., Kotfis, K., Machoy-Mokrzyńska, A., et al. (2021). Kidney damage from nonsteroidal anti-inflammatory drugs—Myth or truth? Review of selected literature. *Pharmacology Research & Perspectives*, 9.
12. Liu, Y., Yang, C., Zhang, J., Ihsan, A., Ares, I., Martínez, M., et al. (2024). Recent progress in adverse events of carboxylic acid non-steroidal anti-inflammatory drugs (CBA-NSAIDs) and their association with metabolism: The consequences on mitochondrial dysfunction and oxidative stress, and prevention with natural plant extracts. *Expert Opinion on Drug Metabolism & Toxicology*, 20, 765–785.
13. Balmanno, A., Falconer, J. R., Ravuri, H. G., & Mills, P. C. (2024). Strategies to improve the transdermal delivery of poorly water-soluble non-steroidal anti-inflammatory drugs. *Pharmaceutics*, 16, 675.
14. Chaubey, G. K., Modanwal, R., Dilawari, R., Talukdar, S., Dhiman, A., Chaudhary, S., et al. (2024). Chronic hyperglycemia impairs anti-microbial function of macrophages in response to *Mycobacterium tuberculosis* infection. *Immunology Research*, 72, 644–653.
15. Özdemir, S. (2024). Inflammation: Complexity and significance of cellular and molecular responses. *Journal of Acute Disease*, 13, 3–7.
16. Rembiałkowska, N., Kocik, Z., Kłosińska, A., Kübler, M., Pałkiewicz, A., Rozmus, W., et al. (2025). Inflammation-driven genomic instability: A pathway to cancer development and therapy resistance. *Pharmaceuticals*, 18, 1406.
17. Zamanian, M. Y., Zafari, H., Osminina, M. K., Skakodub, A. A., Al-Aouadi, R. F. A., Golmohammadi, M., et al. (2024). Improving dexamethasone drug loading and efficacy in treating rheumatoid arthritis via liposome: Focusing on inflammation and molecular mechanisms. *Animal Models and Experimental Medicine*, 8, 5–19.
18. Maddipati, K. R. (2024). Distinct etiology of chronic inflammation—Implications on degenerative diseases and cancer therapy. *Frontiers in Immunology*, 15.
19. Liu, H., Zhang, L., Yu, J., & Shao, S. (2024). Advances in the application and mechanism of bioactive peptides in the treatment of inflammation. *Frontiers in Immunology*, 15.
20. Yoshinaga, M., & Takeuchi, O. (2024). Regulation of inflammatory diseases via the control of mRNA decay. *Inflammation and Regeneration*, 44.
21. Yin, F., He, Y., Li, J., & Gao, Y. (2025). Immune cell senescence in autoimmunity: Implications for disease pathogenesis and therapeutic targeting. *Frontiers in Immunology*, 16.
22. Liu, Z., Yan, J., Zhou, Y., Yin, M., Zhou, R., Shen, J., et al. (2025). Biomimetic immunoregulators for the multi-target inflammation interruption in autoimmune diseases. *ACS Nano*, 19, 27294–27309.
23. Katsanopoulou, M., Zannas, Z., Ofrydopoulou, A., Maria, C., Krokidis, X., Lambropoulou, D. A., et al. (2025). Anti-inflammatory and antiplatelet interactions on PAF and ADP pathways of NSAIDs, analgesic and antihypertensive drugs for cardioprotection—in vitro assessment in human platelets. *Medicina*, 61, 1413.
24. Liu, X., Wang, C., Mao, H., & Wei, J. (2025). Crosstalk between cancer-associated fibroblasts and inflammation in tumor microenvironment: A novel perspective in cancer therapy (Review). *Oncology Reports*, 54, 1–13.
25. Ahmadi, M., Bekeschus, S., Weltmann, K. D., von Woedtke, T., & Wende, K. (2022). Non-steroidal anti-inflammatory drugs: Recent advances in the use of synthetic COX-2 inhibitors. *RSC Medicinal Chemistry*, 13, 471–496.
26. Ferrer, M. D., Busquets-Cortés, C., Capó, X., Tejada, S., Tur, J. A., Pons, A., et al. (2019). Cyclooxygenase-2 inhibitors as a therapeutic target in inflammatory diseases. *Current Medicinal Chemistry*, 26, 3225–3241.
27. Sohail, R., Mathew, M., Patel, K. K., Reddy, S. A., Haider, Z., Naria, M., et al. (2023). Effects of non-steroidal anti-inflammatory drugs (NSAIDs) and gastroprotective NSAIDs on the gastrointestinal tract: A narrative review. *Cureus*, 15.
28. Stiller, C., & Hjemdahl, P. (2022). Lessons from 20 years with COX-2 inhibitors: Importance of dose-response considerations and fair play in comparative trials. *Journal of Internal Medicine*, 292, 557–574.

29. Wang, D., Jiang, Q., Li, P., Yu, C., Yuan, R., Dong, Z., et al. (2025). Orally administrated precision nanomedicine for restoring the intestinal barrier and alleviating inflammation in treatment of inflammatory bowel disease. *ACS Applied Materials & Interfaces*, 17, 10986–11001.
30. Escoter-Torres, L., Greulich, F., Quagliarini, F., Wierer, M., & Uhlenhaut, N. H. (2020). Anti-inflammatory functions of the glucocorticoid receptor require DNA binding. *Nucleic Acids Research*, 48, 8393–8407.
31. Gutiérrez-Brito, J. A., Lomelí-Nieto, J. Á., Muñoz-Valle, J. F., Oregon-Romero, E., Corona-Angeles, J. A., Hernández-Bello, J. (2025). Sex hormones and allergies: Exploring the gender differences in immune responses. *Frontiers in Allergy*, 5.
32. Cao, T. B. T., Quoc, Q. L., Jang, J. H., & Park, H. S. (2024). Immune cell-mediated autoimmune responses in severe asthma. *Yonsei Medical Journal*, 65, 194.
33. Majdalawieh, A. F., Khatib, B. K., & Terro, T. M. (2025). α-Mangostin is a xanthone derivative from mangosteen with potent immunomodulatory and anti-inflammatory properties. *Biomolecules*, 15, 681.
34. Dhurandhar, Y., Tomar, S., Das, A., Prajapati, J. L., Singh, A. P., Bodake, S. H., et al. (2025). Chronic inflammation in obesity and neurodegenerative diseases: Exploring the link in disease onset and progression. *Molecular Biology Reports*, 52.
35. Giollo, A., Adami, G., Gatti, D., Idolazzi, L., & Rossini, M. (2021). Coronavirus disease 19 (COVID-19) and non-steroidal anti-inflammatory drugs (NSAID). *Annals of the Rheumatic Diseases*, 80, e12.
36. Bensman, A. (2020). Non-steroidal anti-inflammatory drugs (NSAIDs) systemic use: The risk of renal failure. *Frontiers in Pediatrics*, 7.
37. Song, M.-H., Yan, Y., Chen, B., Gong, L., Chen, L., Feng, J., et al. (2025). Advances in intra-articular injection hydrogel drug delivery systems in the treatment of rheumatoid arthritis. *Pharmaceutics*, 17, 1118.
38. Wang, Y., Zhao, X., Wang, J., & Zhu, X. (2024). Norisoboldine reduces arthritis severity by attenuating inflammation, oxidative stress, and extracellular matrix degradation in a rat model of rheumatoid arthritis. *Journal of Inflammation Research*, 17, 8839–8852.
39. Riaz, M., Rasool, G., Yousaf, R., Fatima, H., Munir, N., Ejaz, H. (2025). Anti-rheumatic potential of biological DMARDs and protagonistic role of biomarkers in early detection and management of rheumatoid arthritis. *Innate Immunity*, 31.
40. Singh, S., Tiwary, N., Sharma, N., Behl, T., Antil, A., Anwer, M. K., et al. (2024). Integrating nanotechnological advancements of disease-modifying anti-rheumatic drugs into rheumatoid arthritis management. *Pharmaceuticals*, 17, 248.
41. Bhat, M. A., Usman, I., & Dhaneshwar, S. (2024). Application of drug repurposing approach for therapeutic intervention of inflammatory bowel disease. *Current Research in Clinical and Experimental Pharmacology*, 19, 234–249.
42. Siddiq, M. A. B., Clegg, D., Jansen, T. L., & Rasker, J. J. (2022). Emerging and new treatment options for knee osteoarthritis. *Clinical and Experimental Rheumatology*, 18, 20–32.
43. Park, B., Han, G., Jin, D. Y., Gil, K. C., Shin, D., Lee, J., et al. (2024). Mucoadhesive mesalamine prodrug nanoassemblies to target intestinal macrophages for the treatment of inflammatory bowel disease. *ACS Nano*, 18, 16297–16311.
44. Gao, X., Zhou, H., Hu, Z., Wang, Q., Chen, Y., & Zhang, F. (2024). Primary *Clostridium difficile* infection in patients with ulcerative colitis: Case report and literature review. *Medicine*, 103, e36693.
45. Hsiao, S.-W., Yen, H.-H., & Chen, Y.-Y. (2022). Chemoprevention of colitis-associated dysplasia or cancer in inflammatory bowel disease. *Gut and Liver*, 16, 840–848.
46. Hu, S., Zhao, R., Xu, Y., Gu, Z., Zhu, B., & Hu, J. (2024). Orally-administered nanomedicine systems targeting colon inflammation for the treatment of inflammatory bowel disease: Latest advances. *Journal of Materials Chemistry B*, 12, 13–38.
47. Boicean, A., Birlutiu, V., Ichim, C., Anderco, P., Birsan, S. (2023). Fecal microbiota transplantation in inflammatory bowel disease. *Biomedicines*, 11, 1016.
48. Cai, J., Luo, L., Yuan, M., Li, H., Chen, L., Peng, Q., et al. (2025). Baicalein alleviates neuropathic pain by inhibiting microglial activation and inflammation via the TLR4/NF-κB p65 pathway. *Planta Medica*, 91.

49. Ko, K. A., & Lee, D.-K. (2025). Nonsteroidal anti-inflammatory drug-induced peptic ulcer disease. *Korean Journal of Helicobacter and Upper Gastrointestinal Research*, 25, 34–41.
50. Laforge, J. M., Urso, K., Day, J. M., Bourgeois, C. W., Ross, M. M., Ahmadzadeh, S., et al. (2023). Non-steroidal anti-inflammatory drugs: Clinical implications, renal impairment risks, and AKI. *Advances in Therapy*, 40, 2082–2096.
51. Machado, G. C., Abdel-Shaheed, C., Underwood, M., & Day, R. O. (2021). Non-steroidal anti-inflammatory drugs (NSAIDs) for musculoskeletal pain. *BMJ*, 372, n104.
52. Belletti, M., Izquierdo-Escamez, R., Tornero, C., Olivas-Vergara, O., Peiteado, D., & Carreño, E. (2025). Safe use of corticosteroids in non-infectious uveitis. *Journal of Inflammation Research*, 18.
53. Farooq, A., Trehan, S., Singh, G., Arora, N., Mehta, T., Jain, P., et al. (2024). A comprehensive review of low-dose interleukin-2 (IL-2) therapy for systemic lupus erythematosus: Mechanisms, efficacy, and clinical applications. *Cureus*, 16.
54. Yilmaz, O., & Torres, T. (2024). Extended half-life antibodies: A narrative review of a new approach in the management of atopic dermatitis. *Dermatology Therapy (Heidelberg)*, 14, 2393–2406.
55. Komolafe, K., Komolafe, T. R., Crown, O. O., Ajiboye, B., Noubissi, F., Ogungbe, I. V., et al. (2025). Natural products in the management of gastroesophageal reflux disease: Mechanisms, efficacy, and future directions. *Nutrients*, 17, 1069.
56. Jahnavi, K., Pavani Reddy, P., Vasudha, B., & Narender, B. (2019). Non-steroidal anti-inflammatory drugs: An overview. *Journal of Drug Delivery and Therapeutics*, 9, 442–448.
57. Téblick, A., Gunst, J., & Van Den Berghe, G. (2022). Critical illness–induced corticosteroid insufficiency: What it is not and what it could be. *The Journal of Clinical Endocrinology & Metabolism*, 107, 2057–2064.
58. Keller-Wood, M. (2015). Hypothalamic-pituitary–adrenal axis-feedback control. *Comprehensive Physiology*, 5, 1161–1182.
59. Zhang, M., Su, A., Song, H., Zhang, S., Deng, Y., Jing, W., et al. (2025). Inflammatory factors collaboratively link *Helicobacter pylori*-induced gastritis to gastric cancer. *Frontiers in Immunology*, 16.
60. S, D., & R, K. (2024). A review of the regulatory challenges of personalized medicine. *Cureus*, 16.
61. Yi, M., Li, T., Niu, M., Zhang, H., Wu, Y., Wu, K., et al. (2024). Targeting cytokine and chemokine signaling pathways for cancer therapy. *Signaling Transduction Targeted Therapy*, 9.

Cite this article:
Lavanya A*, Rakesh B, Keerthi B, Sankeerthana P, Sneha Rani G. (2026). Pharmacology Of Anti-Inflammatory Drugs: Mechanisms, Clinical Applications, Safety Concerns, And Emerging Targeted Therapies. *Acta Biomedica Scientia*, 13(1), 1-12.